LINCOLN, Neb., Dec. 14, 2023 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that it is collaborating with the Cat Fanciers' Association (CFA), a leading authority in feline advocacy.
The relationship centers around Neogen's My CatScan™ DNA testing services, with the aim of advancing the genomic products available to CFA members through marketing, education, and promotion of Neogen technology and products.
"We are excited about this relationship with the Cat Fanciers' Association," said Dr. Robert Westra, Associate Medical Director at Neogen. "This strategic collaboration will not only advance feline DNA testing but also strengthen the bond between Neogen and the feline community. Both Neogen and CFA look forward to a successful collaboration, driving innovation and awareness in the field of feline genetics."
"Preservation breeding is about careful selection based on ancestry and, most importantly, health and genetic traits," says Desiree Bobby of CFA. "Neogen's My CatScan product screens for over 120 feline health risks and genetic traits and provides data that our breeders need to meticulously shape new generations of pedigreed cats."
The Cat Fanciers' Association, Inc., a not-for-profit association of member clubs and the world's most influential registry of pedigreed cats, has been preserving, celebrating, and protecting cats since 1906. CFA's mission is to preserve and promote the pedigreed breeds of cats and to enhance the well-being of all cats. CFA promotes education, responsible cat ownership, and proper care to the owners of millions of cats worldwide.
About Neogen
Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.
Media Contact
Maree Smith, Marketing Manager — Genomics
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$12.04 |
Daily Change: | 0.02 0.17 |
Daily Volume: | 3,366,036 |
Market Cap: | US$2.610B |
December 17, 2024 October 10, 2024 July 30, 2024 June 27, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORECue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB